A detailed history of Natixis transactions in Biogen Inc. stock. As of the latest transaction made, Natixis holds 107,481 shares of BIIB stock, worth $19.9 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
107,481
Previous 101,738 5.64%
Holding current value
$19.9 Million
Previous $21.9 Million 13.58%
% of portfolio
0.14%
Previous 0.12%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$190.52 - $236.72 $1.09 Million - $1.36 Million
5,743 Added 5.64%
107,481 $24.9 Million
Q1 2024

May 13, 2024

BUY
$212.02 - $267.71 $7.35 Million - $9.28 Million
34,665 Added 51.68%
101,738 $21.9 Million
Q4 2023

Feb 13, 2024

BUY
$222.59 - $267.94 $10.1 Million - $12.2 Million
45,538 Added 211.46%
67,073 $17.4 Million
Q3 2023

Nov 14, 2023

SELL
$253.3 - $285.89 $2.63 Million - $2.97 Million
-10,402 Reduced 32.57%
21,535 $5.53 Million
Q2 2023

Aug 11, 2023

BUY
$275.25 - $318.06 $4.31 Million - $4.98 Million
15,668 Added 96.31%
31,937 $9.1 Million
Q1 2023

May 12, 2023

SELL
$256.56 - $292.34 $33.1 Million - $37.7 Million
-128,995 Reduced 88.8%
16,269 $4.52 Million
Q4 2022

Feb 24, 2023

BUY
$252.44 - $306.72 $14.1 Million - $17.1 Million
55,881 Added 62.52%
145,264 $40.2 Million
Q4 2022

Feb 13, 2023

SELL
$252.44 - $306.72 $683,607 - $830,597
-2,708 Reduced 2.94%
89,383 $24.8 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $8.66 Million - $11.9 Million
-44,500 Reduced 32.58%
92,091 $24.6 Million
Q2 2022

Aug 12, 2022

BUY
$187.54 - $223.02 $8.12 Million - $9.66 Million
43,324 Added 46.45%
136,591 $28 Million
Q1 2022

May 13, 2022

SELL
$193.77 - $244.14 $23.7 Million - $29.9 Million
-122,407 Reduced 56.76%
93,267 $19.6 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $28.5 Million - $36.6 Million
127,089 Added 143.47%
215,674 $51.7 Million
Q3 2021

Nov 12, 2021

SELL
$282.99 - $369.05 $5.3 Million - $6.91 Million
-18,719 Reduced 17.44%
88,585 $25.1 Million
Q2 2021

Aug 13, 2021

BUY
$259.0 - $414.71 $16.6 Million - $26.5 Million
63,990 Added 147.74%
107,304 $37.2 Million
Q1 2021

May 14, 2021

SELL
$242.95 - $284.63 $10.5 Million - $12.3 Million
-43,223 Reduced 49.95%
43,314 $12.1 Million
Q4 2020

Feb 12, 2021

BUY
$236.26 - $355.63 $16.4 Million - $24.8 Million
69,604 Added 411.06%
86,537 $21.2 Million
Q3 2020

Nov 12, 2020

SELL
$264.77 - $305.71 $4.12 Million - $4.75 Million
-15,542 Reduced 47.86%
16,933 $4.8 Million
Q2 2020

Aug 13, 2020

SELL
$258.66 - $342.55 $10.5 Million - $14 Million
-40,786 Reduced 55.67%
32,475 $8.69 Million
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $29.7 Million - $37.6 Million
-110,302 Reduced 60.09%
73,261 $23.2 Million
Q4 2019

Feb 14, 2020

BUY
$220.06 - $304.07 $5.23 Million - $7.22 Million
23,753 Added 14.86%
183,563 $54.3 Million
Q3 2019

Nov 13, 2019

BUY
$217.44 - $243.88 $3.73 Million - $4.19 Million
17,170 Added 12.04%
159,810 $37.2 Million
Q2 2019

Aug 13, 2019

SELL
$219.29 - $241.72 $28.4 Million - $31.3 Million
-129,334 Reduced 47.55%
142,640 $33.4 Million
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $51.3 Million - $80.3 Million
236,794 Added 673.09%
271,974 $63.3 Million
Q4 2018

Feb 14, 2019

SELL
$278.5 - $352.75 $17.2 Million - $21.8 Million
-61,881 Reduced 63.75%
35,180 $10.6 Million
Q3 2018

Nov 14, 2018

SELL
$293.51 - $383.83 $12.8 Million - $16.8 Million
-43,684 Reduced 31.04%
97,061 $34.3 Million
Q2 2018

Aug 14, 2018

BUY
$257.52 - $306.91 $2.49 Million - $2.97 Million
9,687 Added 7.39%
140,745 $40.9 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $8.37 Million - $11.8 Million
32,188 Added 32.56%
131,058 $35.9 Million
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $8.25 Million - $9.24 Million
26,826 Added 37.24%
98,870 $31.5 Million
Q3 2017

Nov 14, 2017

SELL
$281.15 - $329.69 $41.9 Million - $49.2 Million
-149,194 Reduced 67.44%
72,044 $22.6 Million
Q2 2017

Aug 14, 2017

BUY
N/A
221,238
221,238 $60 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $26.6B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.